Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
California Clinical Trials
mi
from
Paramount, CA
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
California Clinical Trials
mi
from
Paramount, CA
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Pasadena Research Institute
mi
from
Pasadena, CA
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Pasadena Research Institute
mi
from
Pasadena, CA
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
CNRI - Los Angeles LLC
mi
from
Pico Rivera, CA
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
CNRI - Los Angeles LLC
mi
from
Pico Rivera, CA
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Clinical Innovations Inc.
mi
from
Riverside, CA
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Clinical Innovations Inc.
mi
from
Riverside, CA
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
CNRI - San Diego, LLC
mi
from
San Diego, CA
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
CNRI - San Diego, LLC
mi
from
San Diego, CA
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
UCSD Medical Center
mi
from
Sandeigo, CA
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
UCSD Medical Center
mi
from
Sandeigo, CA
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Segal Institute for Clinical Research
mi
from
Highlands Ranch, CO
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Segal Institute for Clinical Research
mi
from
Highlands Ranch, CO
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Comprehensive Neuroscience, Inc.
mi
from
Washington,
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Comprehensive Neuroscience, Inc.
mi
from
Washington,
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Florida Clinical Research Center, LLC
mi
from
Fruitland Park, FL
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Florida Clinical Research Center, LLC
mi
from
Fruitland Park, FL
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Booker, J. Gary, MD. APMC
mi
from
Shreveport, LA
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Booker, J. Gary, MD. APMC
mi
from
Shreveport, LA
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Precise Clinical Research
mi
from
Flowood, MS
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Precise Clinical Research
mi
from
Flowood, MS
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
St. Charles Psychiatric Associates
mi
from
St Charles, MO
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
St. Charles Psychiatric Associates
mi
from
St Charles, MO
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
St. Louis Research, Inc
mi
from
St. Louis, MO
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
St. Louis Research, Inc
mi
from
St. Louis, MO
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Comprehensive Neuroscience, Inc
mi
from
Holliswood, NY
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Comprehensive Neuroscience, Inc
mi
from
Holliswood, NY
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Segal Institute for Clinical Research
mi
from
Winston-Salem, NC
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Segal Institute for Clinical Research
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Community Clinical Research
mi
from
Austin, TX
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Community Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Future Search Trials of Neurology
mi
from
Austin, TX
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Future Search Trials of Neurology
mi
from
Austin, TX
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Pillar Clinical Research, LLC
mi
from
Dallas, TX
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Pillar Clinical Research, LLC
mi
from
Dallas, TX
Click here to add this to my saved trials
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated:  3/11/2016
Vijayawada Institute of Mental Health and Neurosciences
mi
from
Vijayawada,
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Status: Enrolling
Updated: 3/11/2016
Vijayawada Institute of Mental Health and Neurosciences
mi
from
Vijayawada,
Click here to add this to my saved trials
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Status: Enrolling
Updated:  3/14/2016
Massachusetts General Hospital
mi
from
Boston, MA
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Status: Enrolling
Updated: 3/14/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Cognitive Rehabilitation in Schizophrenia
The Effects of Cognitive Rehabilitation on Function in Schizophrenia
Status: Enrolling
Updated:  3/14/2016
VA Connecticut Health Care System
mi
from
West Haven, CT
Cognitive Rehabilitation in Schizophrenia
The Effects of Cognitive Rehabilitation on Function in Schizophrenia
Status: Enrolling
Updated: 3/14/2016
VA Connecticut Health Care System
mi
from
West Haven, CT
Click here to add this to my saved trials
Kuvan in People With Schizophrenia and Schizoaffective Disorder
6R-BH 4 in People With Schizophrenia and Schizoaffective Disorder
Status: Enrolling
Updated:  3/17/2016
New York State Psychiatric Institute
mi
from
New York, NY
Kuvan in People With Schizophrenia and Schizoaffective Disorder
6R-BH 4 in People With Schizophrenia and Schizoaffective Disorder
Status: Enrolling
Updated: 3/17/2016
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
A Phase 1 Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Healthy Normal Subjects
Status: Enrolling
Updated:  4/7/2016
Parexel Early Phase
mi
from
Glendale, CA
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
A Phase 1 Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Healthy Normal Subjects
Status: Enrolling
Updated: 4/7/2016
Parexel Early Phase
mi
from
Glendale, CA
Click here to add this to my saved trials
Integrated Coping and Awareness Training
Targeting Stress Reactivity in Schizophrenia: Integrating Coping Awareness Therapy (I-CAT) Pilot Trial
Status: Enrolling
Updated:  4/7/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Integrated Coping and Awareness Training
Targeting Stress Reactivity in Schizophrenia: Integrating Coping Awareness Therapy (I-CAT) Pilot Trial
Status: Enrolling
Updated: 4/7/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
Status: Enrolling
Updated:  4/8/2016
Clinical Research Facility
mi
from
Torrance, CA
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
Status: Enrolling
Updated: 4/8/2016
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
Status: Enrolling
Updated:  4/8/2016
Clinical Research Facility
mi
from
Kissimmee, FL
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
Status: Enrolling
Updated: 4/8/2016
Clinical Research Facility
mi
from
Kissimmee, FL
Click here to add this to my saved trials
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
Status: Enrolling
Updated:  4/8/2016
Clinical Research Facility
mi
from
Conshohocken, PA
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
Status: Enrolling
Updated: 4/8/2016
Clinical Research Facility
mi
from
Conshohocken, PA
Click here to add this to my saved trials
Cognitive Training and Enhanced Supported Employment in Schizophrenia
Cognitive Training and Enhanced Supported Employment
Status: Enrolling
Updated:  4/8/2016
Connecticut Mental Health Center
mi
from
New Haven, CT
Cognitive Training and Enhanced Supported Employment in Schizophrenia
Cognitive Training and Enhanced Supported Employment
Status: Enrolling
Updated: 4/8/2016
Connecticut Mental Health Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Social Cognition Intervention
Augmenting Social Cognitive Intervention for Veterans With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Social Cognition Intervention
Augmenting Social Cognitive Intervention for Veterans With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Anaheim, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
mi
from
Bellevue, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
mi
from
Bellevue, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Escondido, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Escondido, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Garden Grove, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Garden Grove, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Glendale, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Imperial, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Imperial, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Los Angeles, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
National City, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
National City, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Oceanside, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Orange, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Pasadena, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Pico Rivera, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Pico Rivera, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
San Bernardino, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
San Bernardino, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
San Diego, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Sherman Oaks, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Torrance, CA
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Norwalk, CT
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Norwalk, CT
Click here to add this to my saved trials
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Washington,
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials